Key result
Matching RotaTeq antigen yields ~134% higher IgA titers than Rotarix in RotaTeq-vaccinated infants.
Why the study?
Does using a matching vaccine antigen (RotaTeq) compared to a different antigen (Rotarix) improve the estimation of rotavirus IgA antibodies in infants vaccinated with RotaTeq?
Cohort (n=531)
Does using a matching vaccine antigen (RotaTeq) compared to a different antigen (Rotarix) improve the estimation of rotavirus IgA antibodies in infants vaccinated with RotaTeq?
Matching the vaccine antigen in immunoassays yields higher estimations of IgA antibodies, supporting its use for immunogenicity testing.
Answers are grounded in this paper and cite their sources.
Antigen-matched IgA assays may refine immunogenicity estimates post-RotaTeq; leaves open optimal standardization for vaccine trials.
In a clinical trial of Bangladeshi infants who received three doses of RotaTeq (ages 6, 10, and 14 weeks), we did a head-to-head assessment of two vaccine virus strains to measure rotavirus IgA in sera. Serum samples collected at pre-dose 1 (age 6 weeks) and post-dose 3 (age 22 weeks) were tested for rotavirus IgA by EIA by using the matching vaccine strain (RotaTeq) and a different vaccine strain (Rotarix) as antigens. Overall, rotavirus IgA seropositivity and titers with each antigen were compared. At age 22 weeks (N = 531), the proportion of infants who tested rotavirus IgA seropositive was similar when measured using the RotaTeq (412/531 [78%]) or the Rotarix antigen (403/531 [76%]) in the EIA. However, the IgA geometric mean titer was higher when measured using the RotaTeq antigen as compared to that measured using the Rotarix antigen [218 (95%CI: 176–270) vs. 93 (77–111), p < .0001]. We have compared two globally licensed vaccines, the human monovalent, and the pentavalent reassortant, as antigens on a RotaTeq cohort, resulting in higher estimations of IgA antibodies in the same sample when measured using the RotaTeq antigen. Our findings support matching vaccine antigens in EIA for the most desired immunogenicity testing of the RotaTeq vaccine.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a cohort in Rotavirus vaccination (n=531). RotaTeq antigen in EIA vs. Rotarix antigen in EIA was evaluated on IgA geometric mean titer at 22 weeks (p=<.0001). Measuring rotavirus IgA using the matching RotaTeq antigen yielded a higher geometric mean titer compared to the Rotarix antigen in infants vaccinated with RotaTeq.
Synapse has enriched 10 related papers. Consider them for comparative context: